Unraveling tumor microenvironments with spatial genomics: Implications for precision breast cancer therapy
1 Department of International Education College of Western Medicine, Changchun University of Chinese Medicine, China.
2 Department of Histopathology, National Hospital Abuja, Nigeria.
3 Department of Internal Medicine (Consulting group), Obafemi Awolowo University Health Center, Ile-Ife, Nigeria.
4 Department of Medical Laboratory Science, Lead City University, Ibadan, Nigeria.
5 Department of Zoology, Ahmadu Bello University, Zaria, Kaduna, Nigeria.
6 Department of Pharmaceutical Chemistry, University of Ibadan, Nigeria.
7 Department of Anatomy, University of Ilorin, Kwara, Nigeria.
Review
International Journal of Life Science Research Archive, 2025, 09(01), 043-063.
Article DOI: 10.53771/ijlsra.2025.9.1.0045
Publication history:
Received on 07 June 2025; revised on 15 July 2025; accepted on 17 July 2025
Abstract:
Spatial genomics has revolutionized breast cancer research by mapping gene expression within the tumor microenvironment, offering unprecedented insights into the molecular and cellular interactions that drive tumor progression and therapeutic response across luminal A, luminal B, HER2-positive, and triple-negative subtypes. Unlike traditional genomic methods, spatial genomics preserves tissue architecture, revealing subtype-specific TME features, such as immune-rich regions in triple-negative breast cancer and stromal-dense environments in HER2-positive tumors. This review explores spatial genomics technologies, including Visium, GeoMx, and MERFISH, which enable precise TME analysis, highlighting their role in identifying biomarkers like PD-L1 and TGF-β for targeted therapies and immunotherapies. By elucidating TME-driven resistance mechanisms, such as hypoxia in triple-negative tumors or stromal remodeling in HER2-positive cases, spatial genomics informs clinical trials and combination therapies, enhancing patient stratification and treatment efficacy. Despite its promise, challenges including limited resolution, complex data analysis, and high costs hinder clinical adoption. Emerging technologies, artificial intelligence, and multi-omics integration offer solutions, promising higher precision and scalability. This review underscores spatial genomics’ transformative potential to bridge research and clinical practice, paving the way for personalized breast cancer therapies tailored to the dynamic TME, with future advancements poised to redefine treatment paradigms and improve patient outcomes.
Keywords:
Spatial Transcriptomics; Breast Cancer; Tumor Microenvironment; Precision Medicine; Immunotherapy; Biomarker Discovery; Tme Heterogeneity; Multi-Omics Integration
Full text article in PDF:
Copyright information:
Copyright © 2025 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0